Novo Nordisk CEO Mike Doustdar is defending the company's lawsuit against Eli Lilly, escalating a fight over how the two drugmakers market their blockbuster obesity treatments. The dispute centers on advertisements citing a head-to-head trial in which patients receiving the maximum tolerated 10 mg or 15 mg dose of Zepbound lost an average 20.2% of their body weight over 72 weeks, compared with 13.7% for Wegovy. Novo argues that comparison no longer presents the full competitive picture because it used an older Wegovy dose, and the FDA approved Novo's higher 7.2 mg Wegovy dose on March 19, 2026, which Novo says produced average weight loss of 19% over 72 weeks in a separate study. Lilly says it stands firmly behind its advertising, and the commercial stakes are substantial, with Lilly's U.S. Zepbound revenue jumping 44% year over year to $4.9 billion in the second quarter. For investors, the lawsuit is ultimately about competitive positioning rather than legal damages alone, and Novo's September 21 Capital Markets Day is the next major opportunity for management to detail its obesity strategy.
Eli Lilly and CompanyLawsuit challenges Lilly's advertising claims, potentially undermining competitive positioning of Zepbound.
Novo Nordisk A/SNovo's lawsuit defends its competitive position, highlighting FDA approval of higher Wegovy dose.
